Redcliffe Labs sells Crysta IVF to MMG Group’s Moon Care to sharpen diagnostics play

Divestment marks Redcliffe’s strategic pivot toward preventive and advanced diagnostics; Crysta IVF to continue under existing leadership

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga

The Semaglutide Surge: How a diabetes therapy sparked India’s weight loss wave

As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact

Thyrocare’s Bharat Aarogyam score flags silent health risks in 9 out of 10 Indians

Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s

India’s bioeconomy hits $165.7 billion as govt unveils fresh biopharma push

DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports

Punjab joins hands with Roche to roll out ‘NeuroSakhi’ for women with multiple sclerosis

The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab

Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy

SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum

Thyrocare posts strong Q3FY26 results: revenue up 18%, PAT soars 47%

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike

Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar

Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized